Abstract: The disclosure belongs to a field of hydraulic equipment, and in particular to an anti-rolling damping device for floating wind turbines. The specific technical scheme: low ends of buoys are connected with an upper surface of a support plate through a damping assembly, and the damping assembly includes a piston cylinder fixedly arranged on the support plate, a piston plate is slidably arranged in the piston cylinder, a piston rod is arranged at one end of the piston plate far from the support plate, the piston rod extends out of the piston cylinder and is fixedly connected with the buoys, and a plurality of first through holes are arranged on a side wall of the piston cylinder near the lower part. The buoys sink with waves, and the piston plate slides downwards in the piston cylinder.

Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fe region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Abstract: A display apparatus includes: a display; an input interface; and a processor in connection with the display and the input interface and configured to: upon detecting access of a first power amplifier device, output a high-level Hotplug signal at a Hotplug port of the display apparatus; monitor whether a common-mode data packet from the first power amplifier device is received within a first preset duration; in response to the common-mode data packet being received within the first preset duration, send a heartbeat packet to the first power amplifier device, and monitor whether a heartbeat response is received within a second preset duration; in response to the heartbeat response being received within the second preset duration, determine that the first power amplifier device supports e-ARC function; and in response to the heartbeat response being not received within the second preset duration, determine that the first power amplifier device supports ARC function.

Abstract: Disclosed in the present application are a display apparatus and a processing method. According to the method, a data stream from the external device in connection with the display apparatus is received; a device information frame in the data stream is obtained, where the device information frame is a data frame generated by the external device according to a basic transmission protocol between the external device and the display apparatus; marker bits in the device information frame are traversed; in response to the external device supporting the automatic control protocol, a play mode is switched according to usage scenario information added in the data stream; and in response to the external device not supporting the automatic control protocol, a play mode is switched according to a device type of the external device.

Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Abstract: A display apparatus includes: a display; an input interface; and a processor in connection with the display and the input interface and configured to: upon detecting access of a first power amplifier device, output a high-level Hotplug signal at a Hotplug port of the display apparatus; monitor whether a common-mode data packet from the first power amplifier device is received within a first preset duration; in response to the common-mode data packet being received within the first preset duration, send a heartbeat packet to the first power amplifier device, and monitor whether a heartbeat response is received within a second preset duration; in response to the heartbeat response being received within the second preset duration, determine that the first power amplifier device supports e-ARC function; and in response to the heartbeat response being not received within the second preset duration, determine that the first power amplifier device supports ARC function.

Abstract: Provided are methods and compositions for treating kidney disease, such as chronic kidney disease (CKD), in which the methods and compositions comprise antibodies or an antigen binding fragment thereof that specifically and selectively bind to human ?v?8 integrin, which was discovered, as described, to be highly expressed on kidney cells and tissue, and, in particular, diseased or fibrotic kidney tissue. The disclosed anti-?v?8 integrin antibodies bind to human ?v?8 integrin in the kidney and block the activation of TGF-? from its latent form in kidney tissue. The anti-?v?8 antibodies in the disclosed methods reduce, attenuate, or abrogate kidney fibrosis, which is associated with the activities of ?v?8 integrin and TGF-? in kidney tissue. The disclosed antibodies and methods effectively treat kidney disease, in particular, fibrosis associated with kidney disease, such as CKD, in individuals in need thereof.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: Provided herein are antibodies specific for integrin ?v?8 that change the conformation of ?8 so that, upon binding, the ability of ?v?8 to induce release of active, mature TGF? peptide is inhibited.

Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG, constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgGI, e.g., human IgGI), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Abstract: Provided herein are antibodies specific for integrin ?v?8 that change the conformation of ?8 so that, upon binding the ability of ?v?8 to induce release of active, mature TGF? peptide is inhibited.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.